News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Appoints John R. Moore General Counsel
BOULDER, Colo., May 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced the appointment of John R. Moore to the newly created position of vice president and general counsel, effective May 1, 2002. Mr. Moore will oversee Array's legal affairs and will report to the company's Chief Executive Officer, Robert E. Conway.

"We are delighted to have someone of John's caliber and experience join us," said Mr. Conway. "The expertise that John brings to Array will be valuable as we move forward with building our pipeline of proprietary drug candidates and protecting the associated intellectual property."

Mr. Moore joins Array after three years at Wilson Sonsini Goodrich & Rosati as an associate, where he negotiated transactions involving technology, intellectual property and products. Prior to joining Wilson Sonsini Goodrich & Rosati, Mr. Moore was an associate with Kenyon & Kenyon and Arnold White & Durkee, where he focused on intellectual property and licensing matters. Mr. Moore received a J.D. from the University of North Carolina at Chapel Hill School of Law, a M.S. in Biochemistry from the University of Illinois at Urbana-Champaign and a B.S. in Chemistry from the University of North Carolina at Chapel Hill.

About Array BioPharma:

Array BioPharma is a drug discovery company creating small molecule drugs through the integration of chemistry, biology and informatics. Our experienced scientists use an integrated set of drug discovery technologies, which we call the Array Discovery Platform, to invent small molecule drugs in collaboration with leading pharmaceutical and biotechnology companies and to build our own pipeline of proprietary drug candidates. For more information on Array BioPharma, please visit Array's web site at www.arraybiopharma.com .

Array Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed below and described more fully in reports filed by Array with the Securities and Exchange Commission, including our Final Prospectus filed on February 12, 2002. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to collaborate with third parties on their drug discovery activities, the ability of our collaborators and of Array to meet drug discovery objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of May 1, 2002. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

SOURCE Array BioPharma Inc.

CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, thaugeto@arraybiopharma.com